Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 18,99€ (+34,87%). La médiane est de 17,59€ (+24,93%).
| Acheter |
10 |
| Conserver |
2 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » Plus sur finance.yahoo.com
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 0,00 | - |
| Bénéfice brut | 0,00 | - |
| Bénéfice net | −29,88M | 31,30% |
| EBITDA | −29,79M | 31,13% |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 191,93M€ |
Nombre d'actions | 13,62M |
Plus haut/bas sur 52 semaines | 14,96€ - 4,34€ |
| Dividendes | Non |
Bêta | 1,4 |
Ratio P/E | −3,42 |
Ratio PEG | −0,04 |
Ratio P/B | 5,47 |
Ratio P/S | 0,00 |
Profil de l'entreprise
| Nom | Immunic |
| PDG | Erik Lundgren |
| Employés | 95 |
Découvrir des actifs
Les actionnaires de Immunic investissent également dans les actifs suivants
